| Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults RE Wasmann, C Smit, R Ter Heine, SE Koele, EPH van Dongen, ... Journal of Antimicrobial Chemotherapy 74 (4), 978-985, 2019 | 25 | 2019 |
| Early bactericidal activity studies for pulmonary tuberculosis: a systematic review of methodological aspects SE Koele, PPJ Phillips, CM Upton, J van Ingen, USH Simonsson, ... International Journal of Antimicrobial Agents, 106775, 2023 | 6 | 2023 |
| Pharmacokinetically‐guided dosing to improve the efficacy of brigatinib in non‐small cell lung cancer patients SE Koele, SW van Beek, AJ van der Wekken, B Piet, MM van den Heuvel, ... British journal of clinical pharmacology 88 (4), 1930-1934, 2022 | 3 | 2022 |
| Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment SE Koele, SW Van Beek, G Maartens, JCM Brust, EM Svensson Antimicrobial agents and chemotherapy 66 (3), e01749-21, 2022 | 1 | 2022 |
| Power to identify exposure‐response relationships in phase IIa pulmonary tuberculosis trials with multi‐dimensional bacterial load modeling SE Koele, TPC Dorlo, CM Upton, RE Aarnoutse, EM Svensson CPT: Pharmacometrics & Systems Pharmacology, 2023 | | 2023 |
| Micafungin pharmacokinetics in morbidly obese individuals RE Wasmann, SE Koele, C Smit, A Colbers, R ter Heine, EP van Dongen, ... MYCOSES 60, 223-223, 2017 | | 2017 |
| Power to identify exposure-response relationships in phase IIa tuberculosis trials with multi-dimensional bacterial load modeling. SE Koele, TPC Dorlo, CM Upton, R Aarnoutse, EM Svensson | | |
| Population pharmacokinetics of sutezolid and its main metabolite to characterize the exposure-response relationship in patients with pulmonary tuberculosis SE Koele, N Heinrich, C Manyama, S Mpagama, F Mhimbira, M Sebe, ... | | |
